News

WHO downgrades oseltamivir on drugs list after reviewing evidence

BMJ 2017; 357 doi: https://doi.org/10.1136/bmj.j2841 (Published 12 June 2017) Cite this as: BMJ 2017;357:j2841
  1. Zosia Kmietowicz
  1. The BMJ

Oseltamivir (Tamiflu) has been downgraded in the World Health Organization’s list of essential medicines from a “core” drug to one that is “complementary”—a category encompassing drugs that are deemed less cost effective.

Fiona Godlee, The BMJ’s editor in chief, welcomed the move as a victory for the journal’s campaign for evidence based medicine. “WHO’s decision is a vote for evidence based policy making, which will save money and harm. It is also …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe